Physician profile
Michael B Till
NPI 1184665630
$1,772.77
in general payments reported to CMS, 2019-2025
19 companies · $553 in 2025
The $553 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.92 · 2021: $28.55 · 2022: $119 · 2023: $367 · 2024: $620 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $364.41 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $218.60 | 2021-2024 | Bexsero, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $180.96 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $171.06 | 2019-2025 | |
| Abbvie INC. | $167.61 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $142.86 | 2024-2025 | Capvaxive, Gardasil 9 |
| Dexcom, INC. | $90.00 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $81.78 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $70.71 | 2024-2025 | Mounjaro, Zepbound |
| Kaleo, INC. | $69.03 | 2021-2022 | |
| Amgen INC. | $51.16 | 2019-2024 | Repatha, Otezla |
| Becton, Dickinson and Company | $35.57 | 2025 | Bd Veritor Plus Analyzer |
| Astellas Pharma US INC | $23.14 | 2025 | Veozah |
| Tris Pharma INC | $21.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.16 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $18.65 | 2024 | Rexulti |
| Vivus LLC | $16.70 | 2024 | Qsymia |
| Medtronic, INC. | $15.20 | 2024 | Venaseal |
| Corium, LLC | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Till listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.